Munc13-3 Activators
Munc13-3 activators encompass a variety of chemical classes that interact with cellular signaling pathways implicated in synaptic function and neurotransmission. These chemicals can modulate intracellular calcium levels, cyclic AMP (cAMP) concentration, or the activity of neurotransmitter receptors and ion channels. Through these actions, they indirectly influence the conditions that are conducive to the optimal activity of Munc13-3 in the nerve terminal.
Calcium dynamics are central to synaptic vesicle priming, with Munc13-3 being sensitive to changes in intracellular calcium concentration. Compounds like BAPTA-AM, Bay K 8644, and various calcium channel blockers modify calcium influx or buffering, thereby altering the activity landscape for Munc13-3. Enhancing cAMP levels, as achieved by Forskolin and Rolipram, can affect various proteins involved in synaptic plasticity, potentially upregulating the pathways in which Munc13-3 operates. Blockers of ion channels, such as 4-Aminopyridine and Omega-conotoxin GVIA, may increase synaptic demand and compensatory mechanisms, indirectly affecting Munc13-3's role in synaptic vesicle cycling.
SEE ALSO...
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
BAPTA/AM | 126150-97-8 | sc-202488 sc-202488A | 25 mg 100 mg | $138.00 $458.00 | 61 | |
A calcium chelator that can buffer intracellular calcium levels, indirectly maintaining the calcium-dependent activation of Munc13-3 necessary for vesicle priming. | ||||||
Forskolin | 66575-29-9 | sc-3562 sc-3562A sc-3562B sc-3562C sc-3562D | 5 mg 50 mg 1 g 2 g 5 g | $78.00 $153.00 $740.00 $1413.00 $2091.00 | 73 | |
An activator of adenylyl cyclase, increasing cAMP, which can modulate synaptic plasticity mechanisms potentially involving Munc13-3. | ||||||
Rolipram | 61413-54-5 | sc-3563 sc-3563A | 5 mg 50 mg | $77.00 $216.00 | 18 | |
A phosphodiesterase inhibitor that raises cAMP levels, potentially enhancing synaptic transmission processes that involve Munc13-3. | ||||||
(±)-Bay K 8644 | 71145-03-4 | sc-203324 sc-203324A sc-203324B | 1 mg 5 mg 50 mg | $84.00 $196.00 $817.00 | ||
A calcium channel agonist that can increase intracellular calcium concentration, thereby potentially promoting the calcium-dependent function of Munc13-3. | ||||||
(S)-3,5-DHPG | 162870-29-3 | sc-204256 sc-204256A | 5 mg 10 mg | $210.00 $353.00 | 2 | |
An agonist for metabotropic glutamate receptors which can enhance synaptic efficacy, possibly requiring enhanced Munc13-3 activity for vesicle cycling. | ||||||
Nifedipine | 21829-25-4 | sc-3589 sc-3589A | 1 g 5 g | $59.00 $173.00 | 15 | |
A calcium channel blocker that indirectly affects synaptic transmission; its presence may alter the calcium dynamics that Munc13-3 responds to. | ||||||
Ryanodine | 15662-33-6 | sc-201523 sc-201523A | 1 mg 5 mg | $223.00 $799.00 | 19 | |
A modulator of the ryanodine receptor that can affect calcium release from intracellular stores, indirectly impacting Munc13-3 function. | ||||||
Isoproterenol Hydrochloride | 51-30-9 | sc-202188 sc-202188A | 100 mg 500 mg | $28.00 $38.00 | 5 | |
A beta-adrenergic receptor agonist that can increase cAMP and thereby modulate neurotransmitter release mechanisms involving Munc13-3. | ||||||
Verapamil | 52-53-9 | sc-507373 | 1 g | $374.00 | ||
A calcium channel blocker which can modulate calcium influx and thus, may indirectly affect the calcium-dependent regulation of Munc13-3. | ||||||
Nicardipine hydrochloride | 54527-84-3 | sc-202731 sc-202731A | 1 g 5 g | $33.00 $83.00 | 5 | |
Another calcium channel blocker with potential to modulate the activity of calcium-dependent processes, including those associated with Munc13-3. | ||||||